GlobeNewswire by notified

The World of Biolog Gets Bigger! Biolog Adds Contract Services and New Analysis Software to Its Portfolio of Tools With the Acquisition of MIDI Labs and MIDI, Inc.


HAYWARD, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Biolog, Inc., a leading provider of cell-based microbial identification and phenotypic profiling products, today announced the acquisition of MIDI Labs and MIDI, Inc., both headquartered in Newark, Delaware. Biolog and MIDI serve many of the same customers and industries. Over the last two decades, both companies have served the microbial ID community, offering complimentary products and services. The acquisition will be funded through an expansion of Biolog's Series A financing, led by BroadOak Capital and Research Corporation Technologies. 

MIDI Labs, an innovator in microbial identification, currently offers contract laboratory services for microbial identification and enumeration to deliver critical, time-sensitive ID for pharmaceutical, probiotic, food and beverage, and personal care manufacturing operations using sequencing and MALDI-TOF mass spectrometry. MIDI, Inc., a pioneer of microbial identification by fatty acid analysis, offers its Sherlock software packages in various end-markets that enable soil community, spice, botanical, and dietary supplement analysis using GC, GC-MS and HPLC. 

MIDI Labs will supplement its existing offerings with Biolog's OmniLog® platform for metabolic phenotypic analysis. "Combining the technologies from Biolog and MIDI will allow us to offer polyphasic analysis to customers doing any type of microbial ID or phenotypic metabolic profiling to enable a direct link between genotype, phenotype, and proteomics," said Robert Wicke, CEO of Biolog. 

FDA registered, USDA permitted, and ISO 17025: 2017 accredited, MIDI Labs has set the standard in providing accurate and reliable services for 25+ years. "This is a big win for MIDI and our customers. Together with Biolog, we'll be able to identify tens of thousands of microbiota and add phenotypic services for customers needing a more complete picture of an organism's metabolic function," said Gary Jackoway, President of MIDI Labs.

This is Biolog's first acquisition under its new leadership team, which came on board in May 2022. "We are thrilled to welcome the MIDI team into the Biolog family. This acquisition enables rapid expansion of our ID database that will benefit all our ID customers, and with our combination of systems and services, can offer even more value to customers, regardless of scale or budget," said Wicke.

About Biolog

Biolog is a leader in phenotypic cell profiling, metabolic characterization, and microbial identification. Located in Hayward, CA, the company's products enable characterization of microbial cells, mammalian cells and mitochondria as well as identification of thousands of species of bacteria, yeast, and fungi. For more information, visit

Contact Information:
John Proctor, Ph.D.

Related Images

To view this piece of content from, please give your consent at the top of this page.

Image 1: Biolog Logo

This content was issued through the press release distribution service at


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Lerøy Seafood Group ASA: Record revenue in 2023. Progress towards targets for 2025.28.2.2024 06:30:00 CET | Press release

RECORD REVENUE IN 2023. MAKING PROGRESS TOWARDS 2025 TARGETS 2023 marks the first year in Lerøy's history where revenue exceeds NOK 30 billion. Seafood's position among consumers remains strong. We continue to vigorously work towards developing the most efficient and sustainable value chain for seafood. I am proud of the work our employees do, while acknowledging that the past year has been challenging," says CEO Henning Beltestad. FOURTH QUARTER 2023 DEVELOPMENT In the fourth quarter of 2023, Lerøy delivered an operating profit before biomass adjustments of NOK 765 million. In Farming, we experienced challenges related to string jellyfish and lost feeding days in Lerøy Aurora and accelerated harvest in Lerøy Sjøtroll. In Wild Catch, earnings were approximately the same as the same period the year before. In the VAP S&D segment, there is positive development as previously communicated, as product prices has increased, reflecting the increased raw material costs, and we have gradually s

Lerøy Seafood Group ASA: Rekordomsetning i 2023. Fremgang mot mål for 2025.28.2.2024 06:30:00 CET | Pressemelding

REKORDOMSETNING I 2023 2023 er det første året i Lerøy sin historie at omsetningen overstiger NOK 30 mrd. Sjømatens posisjon hos konsumentene står sterkt. Vi fortsetter med full kraft arbeidet med å utvikle den mest effektive og bærekraftige verdikjeden for sjømat. Jeg er stolt av den jobben vi og våre ansatte gjør, samtidig som vi erkjenner at året som har gått har vært utfordrende, sier konsernleder Henning Beltestad. UTVIKLING I FJERDE KVARTAL 2023 I fjerde kvartal 2023 leverte Lerøy et driftsresultat før biomassejusteringer på NOK 765m. I Havbruk opplevde vi utfordringer knyttet til perlesnor-maneter og tap av fôringsdager i Lerøy Aurora og fremskyndet slakting i Lerøy Sjøtroll. Innen Villfangst ble inntjeningen om lag som samme periode året før. I nedstrømsvirksomhetene i segmentet VAP S&D er det som tidligere kommunisert positiv utvikling ettersom produktprisen nå i større grad reflekterer de økte råvarekostnadene, og vi gradvis har lykkes med operasjonelle forbedringer. Styret i

BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)27.2.2024 21:52:04 CET | Press release

Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce site recruitment for BTI-203, a Phase 2 study of recombinant human gelsolin (rhu-pGSN) for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955). The study, A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infections is being conducted under a contract with BARDA’s Division of Research, Innovation, and Ventures (DRIVe), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. Approximately 80 sites

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons27.2.2024 21:42:24 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameAnthony Pagano2.Reason for the notificationa)Position/statusExecutive Vice President & Chief Financial Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction pla

Capital Increase in Genmab as a Result of Employee Warrant Exercise27.2.2024 21:40:01 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 7,325 shares at DKK 1,025.00, 19,631 shares at DKK 1,032.00, 2,473 shares at DKK 1,050.00, 1,422 shares at DKK 1,161.00, 40 shares at DKK 1,334.50, 1,036 shares at DKK 1,362.50, 6,660 shares at DKK 1,402.00, 129 shares at DKK 1,408.00, and 9,713 shares at DKK 1,615.00. Proceeds to the company are approximately DKK 58.7 million. The increase corresponds to approximately 0.07% of the company's share capital. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as

HiddenA line styled icon from Orion Icon Library.Eye